$5.06
0.88% today
Nasdaq, Sep 16, 08:17 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$5.10
-0.01 0.20% 1M
+1.26 32.81% 6M
+0.88 20.85% YTD
+0.35 7.37% 1Y
-11.57 69.41% 3Y
-8.49 62.47% 5Y
-6.78 57.07% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.11 2.20%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Market capitalization $297.28m
Enterprise Value $-81.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 14.82
EV/Sales (TTM) EV/Sales -0.45
P/S ratio (TTM) P/S ratio 1.63
P/B ratio (TTM) P/B ratio 0.55
Revenue growth (TTM) Revenue growth -23.63%
Revenue (TTM) Revenue $182.02m
EBIT (operating result TTM) EBIT $-32.47m
Free Cash Flow (TTM) Free Cash Flow $-5.53m
Cash position $387.68m
EPS (TTM) EPS $-0.19
P/E forward negative
P/S forward 1.48
EV/Sales forward negative
Short interest 6.86%
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
33%
Hold
67%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
193 193
24% 24%
100%
- Direct Costs 17 17
35% 35%
9%
176 176
23% 23%
91%
- Selling and Administrative Expenses 110 110
18% 18%
57%
- Research and Development Expense 77 77
10% 10%
40%
-11 -11
221% 221%
-6%
- Depreciation and Amortization 3.01 3.01
10% 10%
2%
EBIT (Operating Income) EBIT -14 -14
320% 320%
-7%
Net Profit 2.51 2.51
60% 60%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
5 days ago
WASHINGTON , Sept. 11, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2024 Cantor Global Healthcare Conference in New York City on Thursday, September 19, 2024.
Neutral
PRNewsWire
12 days ago
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Neutral
PRNewsWire
18 days ago
WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024. A corporate presentation is scheduled for 11:00 a.m.
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 203
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today